Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.50 |
| ▸ | BCHE | P06276 | 7/20 | 0.50 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6890165 | 1.00 | BACE1 (0.50) | BACE1BCHESLC6A11 | |
| SCHEMBL7305633 | 0.85 | BACE1 (0.60) | BACE1BCHESLC6A11 | |
| SCHEMBL7306846 | 0.85 | BACE1 (0.60) | BACE1BCHESLC6A11 | |
| SCHEMBL4522714 | 0.84 | CCR1 (0.49) | BACE1BCHESLC6A11 | |
| SCHEMBL4522709 | 0.84 | CCR1 (0.49) | BACE1BCHESLC6A11 | |
| SCHEMBL3348155 | 0.84 | BACE1 (0.54) | BACE1BCHESLC6A11 | |
| SCHEMBL3348148 | 0.84 | BACE1 (0.54) | BACE1BCHESLC6A11 | |
| SCHEMBL5439744 | 0.83 | BACE1 (0.51) | BACE1BCHESLC6A11 | |
| SCHEMBL5439746 | 0.83 | BACE1 (0.51) | BACE1BCHESLC6A11 | |
| SCHEMBL6888172 | 0.83 | BACE1 (0.51) | BACE1BCHESLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004502669-A | — | — | 2004-01-29 | — | — | JP | claimed |
| EP-1353898-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | BACE1 4/4885BCHE 12/4885SLC6A11 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.